A5035287097- Cancer Immunotherapy and Biomarkers
- Head and Neck Cancer Studies
- CAR-T cell therapy research
- Cancer Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Treatments and Mutations
- Immunotherapy and Immune Responses
- Cancer Genomics and Diagnostics
- Cancer survivorship and care
- Biosimilars and Bioanalytical Methods
- Brain Metastases and Treatment
- Cancer Research and Treatments
- Childhood Cancer Survivors' Quality of Life
- Virus-based gene therapy research
- Colorectal Cancer Treatments and Studies
- Palliative Care and End-of-Life Issues
- Salivary Gland Tumors Diagnosis and Treatment
- Colorectal and Anal Carcinomas
- Neutropenia and Cancer Infections
- Cancer-related cognitive impairment studies
- Multiple Myeloma Research and Treatments
- Family Support in Illness
- Global Cancer Incidence and Screening
- Economic and Financial Impacts of Cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
Moffitt Cancer Center
2018-2025
University of Washington
2017-2020
Seattle Cancer Care Alliance
2019-2020
Fred Hutch Cancer Center
2017-2018
University of Washington Medical Center
2017
Abstract mRNA-4157 (V940) is an individualized neoantigen therapy targeting up to 34 patient-specific tumor neoantigens induce T-cell responses and potentiate antitumor activity. We report mechanistic insights into the immunogenicity of via characterization from first-in-human, phase 1, KEYNOTE-603 study (NCT03313778) in patients with resected non–small cell lung cancer (Part A: 1-mg mRNA-4157, n = 4) or cutaneous melanoma D: + 200-mg pembrolizumab, 12). Safety, tolerability, were assessed....
Abstract Purpose: A phase II multi-institutional clinical trial was conducted to determine overall survival (OS) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated a combination of cetuximab nivolumab. Patients Methods: R/M HNSCC were 500 mg/m2 i.v. on day 14 as lead-in followed by nivolumab 240 mg 1 15 each 28-day cycle. Expression p16 programmed death-ligand (PD-L1) archived tumors determined. Tumor-tissue–modified human papillomavirus...
Transplant-associated thrombotic microangiopathy (TA-TMA) after allogeneic hematopoietic cell transplantation (HCT) has not been well characterized in large population studies with clinically adjudicated cases. We performed a retrospective cohort study of adults who underwent HCT between 2006 and 2015 to determine the incidence risk factors for TA-TMA describe its natural history response immunosuppressant withdrawal management. Among 2145 patients this study, 192 developed cumulative 7.6%...
We hypothesized the combination of cetuximab and nivolumab would improve survival in recurrent and/or metastatic (R/M) HNSCC by providing synergy cancer control evaluated toxicities efficacy combination. Effects sequential administration anti-Programmed Cell Death-1 checkpoint inhibitors (CPI) were also explored. Patients who failed at least one line palliative treatment for incurable treated with 500 mg/m2 IV on Day (D)-14 as a lead-in followed 240 D1 D15 every 28-D cycle. Electronic health...
Chimeric antigen receptor (CAR) T-cell therapy can lead to durable responses in patients with relapsed/refractory hematologic malignancies. Immune effector cell-associated neurotoxicity syndrome (ICANS) and cytokine release (CRS) are common may place at risk for longer-term cognitive impairment. This study examined changes cognition the first year after CD19-directed CAR lymphoma, as well therapy-specific risk-factors (e.g., ICANS, CRS) nonspecific factors baseline quality of life, frailty)...
766 Background: BASECAMP-1 (NCT04981119) is a pre-screening study to identify patients with tumor-associated human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH) for interventional studies, such as EVEREST-2 (NCT06051695), phase 1/2 logic-gated chimeric receptor T-cell (CAR T) therapy MSLN-expressing cancers. MSLN cell surface protein expressed in several cancer types, including mesothelioma (MESO), colorectal (CRC), non-small lung (NSCLC), ovarian (OVCA), and pancreatic (PANC)...
Immunotherapies, such as CAR-T, have revolutionized cancer treatment for some cancers. However, these treatments often require active participation of a family member or friend to act caregiver at home several weeks after infusion. Given the novelty there is need better understand experience patients receiving and their caregivers. As part larger study, CAR-T caregivers were recruited participate in semi-structured interviews about experiences within week hospital discharge. Guided by Dyadic...
Abstract Purpose: The combination of pembrolizumab (a PD-1 inhibitor) and cabozantinib VEGF has shown promising disease control in recurrent or metastatic head neck cancer (rmHNC). Building on previous research linking plasma metabolites to weight loss, clinical outcomes, survival HNC patients standard therapy, this study evaluates pre- post-treatment as indicators therapeutic response treated with therapy. Methods: In a phase II single-arm trial rmHNC patients, blood was collected before 9...
Background T cell receptor (TCR) signaling profile is a fundamental property that underpins both adaptive and innate immunity in the host. Despite its potential clinical relevance, TCR repertoire peripheral blood has not been thoroughly explored for value as an immunotherapy efficacy biomarker head neck squamous carcinoma (HNSCC). The purpose of present study to characterize compare mononuclear cells (PBMC) from patients with HNSCC treated combination cetuximab nivolumab. Methods We used...
Background: Clinicians must closely monitor patients for toxicities after chimeric antigen receptor T-cell therapy (CAR-T). Patient-reported outcomes (PROs) (e.g., toxicities, quality of life) and activity data steps, sleep) may complement clinicians’ observations. This study tested the feasibility acceptability collecting PROs from with hematologic malignancies during CAR-T explored preliminary patterns. Methods: Participants wore a Fitbit tracker completed at several timepoints through...
TPS2699 Background: Despite the success in hematologic cancers, chimeric antigen receptor (CAR) T-cell therapies are challenging to implement solid tumors owing a lack of tumor-specific targets that discriminate cancer from normal cells. MSLN expression normally is limited mesothelium major body cavities but can be upregulated diverse tumor types (TCGA 2022), making it potential target for therapy. MSLN-targeted cell approaches, including CAR and fusion therapies, have shown promising...
Abstract Adenoid cystic carcinoma (AdCC) is a slow-growing salivary gland malignancy that relapses frequently. AdCCs of the submandibular exhibit unique differences in prognosis and treatment response to adjuvant radiotherapy compared other sites, yet role tumor anatomic subsite on gene expression immune microenvironment (TIME) composition remains unclear. We used 87 samples, including 48 samples (27 AdCC 21 normal tissue samples) from 4 publicly available RNA sequencing datasets, validation...
To enable interrogation of tumor HLA LOH as a clinical diagnostic for precision oncology, we developed and validated an assay that detects within the context FDA-approved test, Tempus xT CDx. Validation was conducted via: (1) analytical evaluation 17 archival patient samples 42 cell line admixtures (2) independent prevalence in HLA-A gene (HLA-A LOH) across 10,982 patients. evaluate prognostic relevance assessed 256 immunotherapy-treated non-small lung cancer (NSCLC) determine feasibility...
Racial/ethnic minority patients with nonhematologic malignancies (non-HM) have lower rates of hospice care, advance directive use, and palliative care utilization than non-Hispanic white (NHW) patients. Less is known regarding racial/ethnic hematologic (HM).To study hospital among HM compare end-of-life outcome measures to non-HM.We performed a retrospective cohort (2010-2015) using electronic health records from an integrated academic center differences in patterns documentation planning...
Patients undergoing radiation therapy (RT) for head and neck squamous cell carcinoma (HNSCC) experience a range of debilitating adverse effects (AEs). Patient-reported outcome (PRO) measures to quantify these AEs are necessary important component health care; however, currently available PRO options often measure only disease-related symptoms or non-RT treatments.